We are looking for outstanding candidates to investigate the effectiveness of base editing and prime editing techniques in mouse zygotes for the development of more effective genetic engineering methods, as well as in post-mitotic retina cell populations to evaluate the potential of these innovative technologies in correcting germline mutations that cause ocular diseases. Through an exploration of the efficacy of these techniques in different cellular environments, this research will contribute to the advancement of precision medicine and gene therapy, with potential implications for the treatment of a variety of genetic disorders.
The successful candidate will focus on the development and applications of CRISPR/Cas-based genome editing technologies for genetic and epigenetic engineering in mouse embryonic stem (ES) cells and mouse models. Solid training in molecular biology and mouse ES cell biology is a must. Preference will be given to recent Ph.D. graduates with strong interests and motivation in developing novel biotechnology for exciting applications in ocular biology.
Salary will be commensurate with education and experience. The position provides generous scientific resources, stipend support, and health benefits. U.S. citizens, U.S. permanent residents, and non-U.S. citizens are eligible to apply.
Interested applicants should submit a cover letter CV with publications, and contact information for three references to Dr. Lijin Dong, PhD, Head, Genetic Core Facility at dongl@nei.nih.gov.
The NIH is dedicated to building a diverse community in its training and employment programs. DHHS, NIH, and NEI are Equal Opportunity Employers.